A company insider recently sold 994 shares of Ironwood Pharmaceuticals Inc. [IRWD]. Should You Sale?

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Ironwood Pharmaceuticals Inc. shares valued at $11,699 were sold by Rickard Jason on Aug 15. At $11.77 per share, Rickard Jason sold 994 shares. The insider’s holdings dropped to 375,736 shares worth approximately $4.4 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, Silver Ronald sold 2,014 shares, netting a total of over 23,705 in proceeds. Following the sale of shares at $11.77 each, the insider now holds 105,151 shares.

Before that, John Minardo had sold 7,330 shares from its account. In a trade valued at $86,274, the Chief Legal Officer traded Ironwood Pharmaceuticals Inc. shares for $11.77 each. Upon closing the transaction, the insider’s holdings decreased to 7,330 shares, worth approximately $1.64 million.

As published in their initiating research note from Piper Sandler on April 22, 2022, Ironwood Pharmaceuticals Inc. [IRWD] has been an Overweight and the price target has been revised to $16. This represents a 26.81% premium over Wednesday’s closing price. Analysts at Wells Fargo downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in late September. As of June 17, 2020, Northland Capital has initiated its “an Outperform” rating for IRWD.

Analyzing IRWD’s Price Performance

On Wednesday, Ironwood Pharmaceuticals Inc. [NASDAQ: IRWD] plunged -2.50% to $11.71. The stock’s lowest price that day was $11.705, but it reached a high of $12.12 in the same session. During the last five days, there has been a drop of approximately -0.93%. Over the course of the year, Ironwood Pharmaceuticals Inc. shares have jumped approximately 0.43%. Shares of the company reached a 52-week high of $12.95 on 03/30/22 and a 52-week low of $10.13 on 02/17/22. A 50-day SMA is recorded $11.70, while a 200-day SMA reached $11.67. Nevertheless, trading volume fell to 1.72 million shares from 1.52 million shares the previous day.

Support And Resistance Levels for Ironwood Pharmaceuticals Inc. (IRWD)

According to the 24-hour chart, there is a support level at 11.57, which, if violated, would cause prices to drop to 11.43. In the upper region, resistance lies at 11.98. The next price resistance is at 12.26. RSI (Relative Strength Index) is 49.85 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.29, which suggests the price will decrease in the coming days. Percent R is at 37.58%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Ironwood Pharmaceuticals Inc. subject to short interest?

Stocks of Ironwood Pharmaceuticals Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 3.43 million shares to 17.51 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 14.08 million shares. A jump of 19.59% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.96 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.96.

Which companies own the most shares of Ironwood Pharmaceuticals Inc. (IRWD)?

According to BlackRock Fund Advisors filings, the company currently owns 24,028,262 shares, which is about 15.62% of the total IRWD shares outstanding. The investor’s shares have appreciated by 12,378,174 from its previous 13-F filing of 11650088.0 shares. With the completion of the sale transaction, Sarissa Capital Management LP’s stake is now worth $187,665,500. Wellington Management Co. LLP reduced a -12.25% interest valued at $173.83 million while Brown Capital Management LLC sold a -2,028,900 stake. A total of 1,184,945 shares of Ironwood Pharmaceuticals Inc. were sold by The Vanguard Group, Inc. during the quarter, and 418,756 were bought by SSgA Funds Management, Inc. In its current portfolio, LSV Asset Management holds 7,479,157 shares valued at $85.64 million.

In terms of Ironwood Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $12.75 in the next 12 months, up nearly 8.24% from the previous closing price of $12.01. Analysts anticipate Ironwood Pharmaceuticals Inc. stock to reach $16.00 by 2022, with the lowest price target being $9.00. In spite of this, 4 analysts ranked Ironwood Pharmaceuticals Inc. stock as a Hold at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here